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Abstract: Clinical data indicate that patients with C-reactive protein (CRP) levels higher than
2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardio-
vascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could
predict recurrent events in patients with low or persistent inflammation and coronary artery disease
(CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3,
monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide
(NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovas-
cular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death).
Patients with persistent inflammation (n = 343) showed higher NT-proBNP and MCP-1 plasma levels
compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with
primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels
were associated with increased risk of the primary outcome in patients with persistent inflammation.
When patients were divided by type of event, MCP-1 was associated with an increased risk of acute
ischemic events. A significant interaction between MCP-1 and persistent inflammation was found
(synergy index: 6.17 (4.39–7.95)). In conclusion, MCP-1 plasma concentration is associated with
recurrent cardiovascular events in patients with persistent inflammation.
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1. Introduction
Clinical and experimental data support an essential role for inflammation in atherothrom-
bosis [1,2]. Inflammation contributes to the genesis and progression of atherosclerotic
plaque development from the initial steps to plaque rupture, which underlies many acute
ischemic events. Several inflammatory-related mechanisms are involved in various aspects of
atherosclerosis, including immune cell recruitment, cell adhesion, collagen and matrix degra-
dation, smooth muscle cell proliferation, platelet aggregation and thrombus formation [3].
From a clinical point of view, different emerging inflammatory biomarkers have been tested
to identify individuals at risk for the first and recurrent cardiovascular events. Of these, acute
phase C-reactive protein (CRP) is a circulating pentraxin that induces a number of activities in
cells and tissues involved in the processes of atherothrombosis [4]. CRP is also a stable plasma
biomarker for systemic inflammation. Blood levels of CRP depend on interleukin 6 and other
inflammatory proteins and cytokines that activate its production in alveolar macrophages,
hepatocytes, monocyte-derived macrophages and lymphocytes in atherosclerotic plaque [5].
It has been extensively demonstrated that CRP levels are associated with an increased
risk of cardiovascular events, independently of cholesterol levels [6,7]. Thus, the Monitor-
ing of Trends and Determinants in Cardiovascular Disease (MONICA) study demonstrated
that elevated levels of CRP were associated with an increased risk of coronary events in
healthy middle-aged men [8]. In addition, CRP levels also predicted cardiovascular risk in
women [7]. Clinical guidelines recommend the use of CRP as a part of global risk prediction
and suggest that levels of CRP of <1, 1 to <3, and ≥3 mg/L can be used to represent low,
moderate, and high vascular risk [9]. Nowadays, it is considered that patients with CRP
levels higher than 2 mg/L are on persistent inflammation [10].
Additional biomarkers may refine risk due to inflammation after a coronary syndrome.
For this reason, we tested whether the combination of CRP concentrations with other
biomarkers could potentially help to predict risk in patients with persistent inflammation.
Thus, we selected a panel of biomarkers associated with higher risk of cardiovascular (CV)
events [11], including monocyte chemoattractant protein-1 (MCP-1) and galectin-3, both in-
volved in inflammation and atherosclerosis [12,13]; N-terminal fragment of brain natriuretic
peptide (NT-proBNP), which is related with heart failure (HF); and Troponin I, a marker of
myocardial injury. Based on CRP concentrations, 917 patients with stable coronary artery
disease (CAD; those who suffered a previous acute coronary syndrome or myocardial
infarction 6 to 12 months before) were divided in two groups, low (CRP < 2 mg/L) or
persistent (CRP ≥ 2 mg/L) inflammation.
2. Results
From 917 patients with acute coronary syndrome, 574 had low inflammation
(CRP < 2 mg/L) and 343 had persistent inflammation (CRP ≥ 2 mg/L). The clinical and
demographic characteristics of the studied population according to CRP concentrations
are summarized in Table 1. There were significant differences among groups with re-
spect to body mass index, smokers and patients previously diagnosed with hypertension,
diabetes and heart failure. Patients with persistent inflammation had higher levels of
total cholesterol, LDL-c and triglycerides. They had also diminished GFR and showed
higher percentages of coronary artery bypass and vessels affects and had less complete
revascularization and previous acute ischemic events. Finally, these patients were more
often under treatment with acenocumarol, oral antidiabetic drugs, diuretics and nitrates.
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Table 1. Characteristics of the studied population according to C-reactive protein (CRP) concentrations.
Parameter Patients with CRP < 2 mg/L(n = 574)
Patients with CRP ≥ 2 mg/L
(n = 343) p-Value
Age (year) 60 (52–71) 61 (51–72) 0.686
Male sex (%) 76.3 74.9 0.637
Body mass index (kg/m2) 27.7 (25.1–30.2) 28.7 (26.6–32.0) <0.001
Smoker (%) 73.0 79.3 0.032
Hypertension (%) 61.0 68.2 0.027
Diabetes (%) 20.9 28.3 0.011
Previous heart failure (%) 9.6 15.2 0.011
Cerebrovascular event (%) 1.9 4.1 0.051
Present or past atrial fibrillation (%) 5.7 6.7 0.558
Total Cholesterol (mg/dL) 140 (121–158) 154 (134–172) <0.001
LDL Cholesterol (mg/dL) 75 (63–89) 83 (68–99) <0.001
HDL Cholesterol (mg/dL) 41 (35–48) 41 (36–47) 0.686
Triglycerides (mg/dL) 93 (72–125) 120 (89–167) <0.001
Glucose (mg/dL) 101 (91–112) 100 (92–118) 0.243
GFR (CKD-EPI) (mL/min/1.73 m2) 81 (68–94) 77 (60–90) <0.001
High-sensitivity C-reactive protein (mg/L) 0.5 (0.1–1.0) 4.1 (2.8–7.3) <0.001
High-sensitivity troponin I (ng/L) 3.0 (0.0–9.0) 3.5 (0.0–12.0) 0.152
NT-ProBNP (ng/L) 165 (87–350) 188 (96–481) 0.034
MCP-1 (ng/L) 129 (103–171) 142 (111–180) 0.006
Galectin-3 (µg/L) 7.8 (6.0–9.7) 7.8 (5.8–10.0) 0.942
Medical Therapy
Acetylsalicylic acid (%) 94.6 91.2 0.049
AntiP2Y12 (%) 78.9 67.6 <0.001
Acenocumarol (%) 4.2 7.9 0.018
Statins (%) 95.5 93.0 0.111
Oral antidiabetic drugs (%) 13.6 21.3 0.002
Insulin (%) 5.4 7.9 0.137
ACE inhibitors (%) 64.0 55.7 0.013
Angiotensin receptor blockers (%) 14.8 18.1 0.192
Aldosterone receptor blockers (%) 7.3 4.4 0.074
Betablockers (%) 79.6 77.2 0.399
Diuretics (%) 15.8 23.3 0.005
Nitrates (%) 11.5 17.2 0.015
Data at Last Acute Coronary Event
STEMI/Non-STEACS (%) 53.0 42.0 <0.001
Number of vessels diseased 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.001
Coronary artery bypass graft (%) 5.6 11.1 0.002
Complete revascularization (%) 72.1 64.7 0.019
CRP, C-reactive protein; GFR, glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; NT-proBNP, N-
terminal fragment of brain natriuretic peptide; MCP-1, monocyte chemoattractant protein-1; antiP2Y12, inhibitor of receptor for adenosine
diphosphate (ADP) P2Y12; ACE, Angiotensin-converting enzyme; STEMI, ST-elevation myocardial infarction; Non-STEACS, non-ST
elevation acute coronary syndrome.
With respect to the biomarkers analyzed, NT-proBNP and MCP-1 plasma levels
were increased in patients with persistent inflammation compared with those with low
inflammation. No changes were observed in Tn-I or Galectin-3 plasma levels between
patients with low or persistent inflammation.
2.1. Biomarkers and Primary Outcome
We focused our analysis on the role of NT-proBNP and MCP-1 plasma levels as
predictors of outcomes, since these biomarkers were the only ones showing differences
between patients with low or persistent inflammation. Primary outcome was determined
from the day of examination onward, with a mean follow-up of 4.59 ± 2.39 years. During
follow-up, 183 patients—95 with low and 88 with persistent inflammation—developed the
primary end point. The univariate Cox proportional hazard models used are summarized
in Tables S1 and S2. A multivariate Cox model was used to study the effects of variables
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that were statistically significant in the univariate analysis (Table 2). After adjustment, age
(hazard ratio (HR): 1.03 (1.00–1.05); p = 0.028) was associated with an increased risk of
developing the primary outcome in patients with low inflammation. In addition, patients
taking statins or β-blockers showed a low risk for the outcome (HR: 0.43 (0.20–0.89),
p = 0.023; HR: 0.54 (0.34–0.84), p = 0.007, respectively). No association was observed
between NT-proBNP or MCP-1 plasma levels and the primary outcome in patients with
low inflammation (Table 2).
Table 2. Multivariate Cox proportional hazard model for the incidence rates of acute ischemic events,
heart failure and death.
CRP < 2 mg/L
Parameter HR (95% CI) p-Value
Age, years 1.03 (1.00–1.05) 0.028
Diabetes, yes 1.32 (0.65–2.66) 0.445
Hypertension, yes 1.64 (0.91–2.96) 0.098
History of CVE, yes 2.51 (0.97–6.45) 0.057
Ejection fraction < 40%, yes 1.00 (0.49–2.06) 0.997
CKD-EPI < 60 mL/min/1.73 m2 1.04 (0.59–1.82) 0.906
Statins, yes 0.43 (0.20–0.89) 0.023
ACE inhibitors, yes 0.77 (0.45–1.34) 0.364
ARB, yes 1.75 (0.93–3.29) 0.238
Antialdosterone, yes 1.58 (0.74–3.39) 0.238
β-Blockers, yes 0.54 (0.34–0.84) 0.007
Nitrates, yes 1.39 (0.83–2.31) 0.207
Diuretics, yes 0.81 (0.46–1.41) 0.456
Insulin, yes 1.40 (0.64–3.08) 0.401
Oral antidiabetic drugs, yes 1.34 (0.62–2.92) 0.458
NT-proBNP, 1-SD 1.14 (0.96–1.35) 0.144
MCP-1, 1-SD 1.07 (0.88–1.28) 0.493
Tn-I, 1-SD 1.05 (0.70–1.58) 0.815
CRP ≥ 2 mg/L
Parameter HR (95% CI) p-Value
Age, years 1.02 (1.00–1.04) 0.073
Sex, male 0.80 (0.48–1.32) 0.381
Hypertension, yes 0.93 (0.52–1.65) 0.803
Ejection fraction < 40%, yes 1.60 (0.88–2.92) 0.126
Atrial Fibrillation, yes 2.36 (1.04–5.33) 0.039
Acute myocardial infarction, yes 0.58 (0.34–0.99) 0.046
Complete Revascularization 0.59 (0.36–0.95) 0.029
LDL-c, mg/dL 1.01 (1.00–1.01) 0.091
HDL-c, mg/dL 1.02 (1.00–1.04) 0.081
Anticoagulants, yes 0.77 (0.34–1.74) 0.531
Statins, yes 0.44 (0.23–0.86) 0.016
Nitrates, yes 1.64 (0.93–2.90) 0.085
Diuretics, yes 1.04 (0.62–1.77) 0.874
Insulin, yes 2.14 (1.07–4.28) 0.031
NT-proBNP, 1-SD 1.22 (1.06–1.41) 0.007
MCP-1, 1-SD 1.26 (1.02–1.56) 0.032
Gal-3, 1-SD 1.16 (0.93–1.46) 0.192
Tn-I, 1-SD 1.18 (0.95–1.32) 0.136
CRP, C-reactive protein; HR, Hazard ratio; CVE, cardiovascular event; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration; ACE, Angiotensin-converting enzyme; ARB, angiotensin II recepotr blockers; NT-
proBNP, N-terminal fragment of brain natriuretic peptide; MCP-1, monocyte chemoattractant protein-1; Tn-I,
troponin I; Gal-3, galectin-3.
In patients with persistent inflammation, the presence of atrial fibrillation (HR: 2.36
(1.04–5.33); p = 0.039), previous acute myocardial infarction (HR: 0.58 (0.34–0.99); p = 0.046)
and complete revascularization (HR: 0.59 (0.34–0.99); p = 0.029) persisted as predictors
of primary outcome after multivariate Cox analysis. In addition, patients taking statins
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showed a low risk for the outcome (HR: 0.48 (0.25–0.93); p = 0.029). However, patients
receiving insulin showed a high risk for the outcome (HR: 2.14 (1.07–4.28); p = 0.031). Both
NT-proBNP (HR: 1.22 (1.06–1.41); p = 0.007) and MCP-1 (HR: 1.26 (1.02–1.56); p = 0.032)
plasma levels were associated with an increased risk of developing the primary outcome in
patients with persistent inflammation.
2.2. MCP-1 and Acute Ischemic Events
To delimitate the roles of MCP-1 and NT-proBNP as cardiovascular risk biomarkers,
secondary outcomes (acute ischemic events, heart failure or death) were analyzed. The
predictors for acute ischemic events were studied in both patients with low and persistent
inflammation. During the follow-up, 125 patients—61 with low and 54 with persistent
inflammation—suffered an acute ischemic event. The univariate Cox proportional hazard
models are summarized in Supplementary Tables S1 and S2. In the multivariate Cox
analysis, no associations were observed between any variables analyzed and risk for acute
ischemic events in patients with low inflammation.
LDL-c plasma levels (HR: 1.01 (1.00–1.02); p = 0.003) and insulin treatment (HR: 2.74
(1.32–5.70); p = 0.007) were associated with an increased risk of acute ischemic events
in patients with persistent inflammation. In addition, patients taking statins (HR: 0.41
(0.20–0.84); p = 0.015) or with previous complete revascularization (HR: 0.49 (0.28–0.83);
p = 0.009) were associated with a decreased risk for acute ischemic events. Interestingly,
MCP-1 was the only biomarker that persisted as predictor for acute ischemic events after
adjustment by confounders (HR: 1.31 (1.07–1.62); p = 0.010).
Since both MCP-1 and CRP are proinflammatory, we explored the potential additive
effects of CRP and MCP-1 in relation to outcome. MCP-1 cut-off value was identified using
a receiver operating characteristic curve (ROC) and the Youden’s index, and was established
at 188 ng/L. Thus, we divided the patients into three groups as follows: group 1 included
patients with low inflammation (CRP ≤ 2 mg/L, n = 468) as a reference, group 2 included
patients with persistent inflammation and low MCP-1 (n = 277) and group 3 included
patients with persistent inflammation and high MCP-1 (n = 66). The Kaplan–Meier curve
showed a significant association between high MCP-1 levels and persistent inflammation,
with a reduction in the number of patients who remained event-free compared with those
with low MCP-1 or patients with low CRP (log rank test 21.04; p < 0.001) (Figure 1).
In the univariate analysis, patients from group 3 had a significantly increased risk of
ischemic events (HR: 2.68 (1.63–4.41); p > 0.001). Group 3 persisted as an independent pre-
dictor of ischemic events after adjustment by confounders (HR: 2.08 (1.25–3.47); p = 0.005)
(Table 3).
Table 3. Multivariate Cox proportional hazard model for the incidence of recurrent acute ischemic
events in patients with CAD.
Parameter HR (95% CI) p-Value
Complete Revascularization 0.62 (0.43–0.91) 0.014
LDL-c, mg/dL 1.01 (1.00–1.01) 0.022
Statins, yes 0.45 (0.25–0.79) 0.006
Insulin, yes 2.32 (1.35–3.99) 0.002
CRP < 2 mg/L 1.00
CRP ≥ 2 mg/L, MCP-1 ≤ 188 ng/L 0.79 (0.52–1.21) 0.280
CRP ≥ 2 mg/L, MCP-1 > 188 ng/L 2.08 (1.25–3.47) 0.005
HR, Hazard ratio; LDL-c, low-density lipoprotein-cholesterol; CRP, C-reactive protein; MCP-1, monocyte chemoat-
tractant protein-1.
Biologic interaction effects were calculated for crude and adjusted HR. In crude
analysis, high MCP-1 levels showed a significant interaction (synergy index S = 12.3 (95%
CI: 9.75–14.9)) with persistent inflammation. The relative excess risk due to interaction
(RERI) was 2.98 (95% CI: 1.44–4.52). After adjustment for confounding factors, the S was
6.17 (95% CI: 4.39–7.95) and the RERI was 2.37 (95% CI: 1.08–3.66).
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Figure 1. Kaplan–Meier plot of cumulative probability of an acute ischemic event when patients
were grouped according to C-rective protein (CRP) and monocyte chemoattractant protein-1 (MCP-1)
levels. CRP concentrations were defined as low (CRP < 2 mg/L) and high levels (CRP ≥ 2 mg/L).
MCP-1 levels were defined as low MCP-1 (≤188 ng/L) or high MCP-1 (>188 ng/L), as determined
by receiver operator characteristic curves.
2.3. NT-proBNP and HF or Death
The predictors for HF or death were studied using univariate Cox analyses in both
patients with low and persistent inflammation (Tables S1 and S2). During the follow-up,
96 patients—45 with low and 51 with persistent inflammation—suffered HF or death. After
adjustment, age (HR: 1.08 (1.04–1.12); p < 0.001), LDL-c (HR: 0.98 (0.97–1.00); p = 0.034),
taking antialdosterone antagonists (HR: 3.01 (1.12–8.08); p = 0.029) or β-blockers (HR: 0.40
(0.20–0.80); p = 0.029) was a predictor for HF or death in patients with low inflammation
(Table 4). In addition, age (HR: 1.07 (1.03–1.10); p < 0.001), ejection fraction < 40% (HR: 2.60
(1.22–5.51); p = 0.012), HDL-c plasma levels (HR: 1.05 (1.02–1.08); p = 0.001) and treatment
with insulin (HR: 3.22 (1.28–8.13); p = 0.013) were associated with an increased risk of
developing HF and death in patients with persistent inflammation (Table 4). NT-proBNP
plasma levels persisted as independent predictors of HF or death after adjustment in
patients with either low or persistent inflammation (HR: 1.27 (1.03–1.57), p = 0.024; HR: 1.39
(1.16–1.66), p < 0.001, respectively) (Table 4).
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Table 4. Multivariate Cox proportional hazards model for the incidence of heart failure and death.
CRP < 2 mg/L
Parameter HR (95% CI) p-Value
Age, years 1.08 (1.04–1.12) <0.001
Body mass index, kg/m2 0.97 (0.89–1.06) 0.498
Diabetes, yes 2.89 (1.01–8.28) 0.048
Hypertension, yes 1.61 (0.53–4.93) 0.402
History of CVE, yes 0.97 (0.19–4.95) 0.969
Ejection fraction < 40%, yes 1.06 (0.41–2.74) 0.906
LDL-c, mg/dL 0.98 (0.97–1.00) 0.034
CKD-EPI < 60 mL/min/1.73 m2 0.99 (0.44–2.25) 0.906
Anticoagulants, yes 1.60 (0.44–5.87) 0.475
Statins, yes 0.46 (0.14–1.50) 0.200
Antialdosterone, yes 3.01 (1.12–8.08) 0.029
β-Blockers, yes 0.40 (0.20–0.80) 0.009
Nitrates, yes 1.08 (0.50–2.36) 0.837
Diuretics, yes 1.27 (0.56–2.86) 0.563
Insulin, yes 1.33 (0.42–4.20) 0.630
Oral antidiabetic drugs, yes 1.00 (0.32–3.11) 0.997
NT-proBNP, 1-SD 1.27 (1.03–1.57) 0.024
MCP-1, 1-SD 1.13 (0.85–1.49) 0.140
Tn-I, 1-SD 1.33 (0.91–1.95) 0.140
CRP ≥ 2 mg/L
Parameter HR (95% CI) p-Value
Age, years 1.07 (1.03–1.10) <0.001
Sex, male 0.99 (0.49–2.02) 0.980
Hypertension, yes 0.82 (0.36–1.88) 0.644
History of CVE, yes 2.11 (0.43–10.3) 0.358
Ejection fraction < 40%, yes 2.60 (1.22–5.51) 0.012
Atrial Fibrillation, yes 3.61 (1.28–10.1) 0.015
Complete Revascularization 0.76 (0.39–1.47) 0.413
HDL-c, mg/dL 1.05 (1.02–1.08) 0.001
CKD-EPI < 60 mL/min/1.73 m2 0.70 (0.35–1.41) 0.319
Anticoagulants, yes 0.56 (0.20–1.59) 0.279
Statins, yes 0.44 (0.17–1.16) 0.096
Antialdosterone, yes 0.55 (0.13–2.32) 0.414
Nitrates, yes 1.98 (0.89–4.43) 0.094
Diuretics, yes 1.11 (0.55–2.28) 0.765
Insulin, yes 3.22 (1.28–8.13) 0.013
NT-proBNP, 1-SD 1.39 (1.16–1.66) <0.001
MCP-1, 1-SD 1.01 (0.74–1.38) 0.931
Gal-3, 1-SD 1.50 (0.93–3.08) 0.094
Tn-I, 1-SD 1.26 (0.90–1.43) 0.234
CRP, C-reactive protein; HR, Hazard ratio; CVE, cardiovascular event; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration; ACE, Angiotensin-converting enzyme; ARB, angiotensin II recepotr blockers; NT-
proBNP, N-terminal fragment of brain natriuretic peptide; MCP-1, monocyte chemoattractant protein-1; Tn-I,
troponin I; Gal-3, galectin-3.
3. Discussion
In this work, we investigated Tn-I, NT-proBNP, MCP-1 and Gal-3 plasma levels as
predictors of recurrent cardiovascular events (acute ischemic events, heart failure and death)
in patients with stable CAD and low or persistent inflammation. We observed that NT-
proBNP and MCP-1 plasma levels were increased in patients with persistent inflammation.
However, no changes were observed in Gal-3 or Tn-I levels, depending on the inflammatory
status. Both MCP-1 and NT-proBNP plasma levels were associated with an increased risk
of developing the primary outcome in patients with persistent inflammation. Our results
also showed that NT-proBNP was associated with an increased risk of HF or death in
patients with both low and persistent inflammation. More importantly, we showed that
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MCP-1 might be an additive biomarker for recurrent ischemic events only in patients with
persistent inflammation.
MCP-1, a member of the C-C chemokine family, is synthetized by endothelial cells,
smooth muscle cells and monocytes and macrophages within atherosclerotic plaques [14].
Oxidized LDL, different cytokines, homocysteine, angiotensin II, shear stress and other
mediators of atherosclerosis induce MCP-1 production in vascular cells [15]. It is known
that MCP-1, through its receptor C-C chemokine receptor type 2 (CCR-2) on monocytes, acts
as a chemotactic factor to recruit monocytes into the vascular wall [16]. MCP-1 is highly
expressed in human macrophage-rich atherosclerotic plaques [17]. The role of MCP-1
in atherosclerotic plaque development and progression has been extensively analyzed.
Atherosclerosis is promoted when MCP-1 expression is increased in the carotid artery of
rabbits [16]. Dominant-negative mutation of MCP-1 prevents vulnerable plaques from
rupture in rabbits, independent of their lipid levels [18]. In addition, MCP-1 deletion
reduced atherosclerosis progression in transgenic mice overexpressing human ApoB [19]
and in low-density-receptor-deficient mice [20]. A significant reduction in atherosclerotic
lesion size was also observed in CCR-2-deficient mice [21].
At a population level, MCP-1 plasma concentrations are positively correlated with
different cardiovascular risk factors [22]. Higher MCP-1 plasma levels were observed in
patients with stable coronary heart disease in the MONICA study [23] and with peripheral
artery disease in the Atherosclerosis Risk in Communities study [24]. Elevated MCP-1
plasma levels have been also associated with an increased risk for myocardial infarction and
death in patients with acute coronary syndrome [25]. In addition, MCP-1 concentrations
provided independent prognostic value in the acute and chronic phases after acute coronary
syndrome in the Aggrastat to Zocor trial (A to Z) [26]. Accordingly, we previously observed
that MCP-1 is associated with cardiovascular events in patients with CAD [11]. In this study,
we found that higher MCP-1 plasma levels were specifically associated with recurrent acute
ischemic events in patients with systemic inflammation. The association of MCP-1 with
acute ischemic events was strongest in patients with persistent inflammation, in whom high
MCP-1 significantly predicted recurrent events. In fact, interaction between CRP and MCP-
1 was observed even after adjusting for confounder factors. Thus, the HR for patients with
both persistent inflammation and elevated MCP-1 levels was 6.17 times higher than the
sum of the independent relative risk for each separately. These data indicates that MCP-1
levels offered prognostic information that was independent of that provided by CRP.
From a clinical point of view, reduction of the inflammatory response has been shown
to be beneficial in decreasing cardiovascular events. Anti-inflammatory therapy targeting
the interleukin-1β with canakinumab in the Canakinumab Antiinflammatory Thrombosis
Outcome Study (CANTOS) study was associated with a significantly lower proportion of
recurrent cardiovascular events independent of lipid levels in patients with acute myocar-
dial infarction and CRP > 2 mg/L [27]. In addition, the Low Dose of Colchicine (LoDoCo)
study showed that colchicine administered in addition to statins and other therapies ap-
peared effective for the prevention of cardiovascular events (CVE) in patients with stable
CAD [28]. In addition, the LoDoCo2 study demonstrated that the risk of cardiovascular
events was significantly lower among those who received 0.5 mg of colchicine once daily
than among those who received placebo [29]. Given the clear role of MCP-1 in atheroscle-
rosis development and its complications, as well as the association of MCP-1 plasma levels
with risk for future and recurrent acute ischemic events, MCP-1 should be further studied
as a therapeutic target for the treatment of atherosclerosis. In fact, propagermanium, a drug
used clinically for the treatment of chronic hepatitis in Japan, inhibits C-C chemokine recep-
tor 2 function and reduces macrophage infiltration and atherosclerosis in Apolipoprotein E
(ApoE) knockout mice [30]. This has recently been reported in a phase I dose escalation trial
with propagermaium in patients with breast cancer [31] and a phase 2 trial with anti-MCP-1
(carlumab) in patients with idiopatic pulmonary fibrosis [32]. In addition, MLN1202, a
specific humanized monoclonal antibody that interacts with CCR2-inhibiting MCP-1 bind-
ing, was used in a randomized, double-blind, placebo-controlled study in patients at
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risk for atherosclerotic cardiovascular disease (2 or more risk factors for atherosclerotic
cardiovascular disease and circulating CRP >3 mg/L) [33]. MLN1202 was well tolerated
and resulted in significant reductions in CRP. In addition, a randomized, double-blind,
placebo-controlled phase 2a study to assess the effects of MLN1202 on atherosclerotic
inflammation in subjects with stable atherosclerotic cardiovascular disease was started in
2015 (NCT02388971). However, this study was withdrawn during the recruitment phase
for unknown reasons. Overall, if these therapies are proven to be safe and beneficial,
investigation in atherosclerosis patients may be warranted.
Finally, NT-proBNP concentrations were associated with heart failure or death in both
patients with low and persistent inflammation. These data are in accordance with several
studies in which NT-proBNP concentrations were proven to be powerful diagnostic and
prognostic biomarkers of heart disease [34].
Our study has some limitations. The use of the optimal cut-off point obtained for MCP-
1 was used in combination with CRP in the same population, which could introduce a bias
to our results. The limited size of patients with high MCP-1 and persistent inflammation
may have influenced the results. Additionally, changes in MCP-1 during follow-up were
not explored. However, the A to Z trial showed that MCP-1 levels did not change during
follow-up after acute coronary syndrome [26]. Finally, data from the Biomarkers in Acute
Coronary Syndrome & Biomarkers in Acute Myocardial Infarction (BACS-BAMI) database
were used, however the findings reported here are different from those reported in previous
papers [11,35].
In conclusion, our study demonstrates that MCP-1 plasma levels are independently
associated with recurrent acute ischemic events in patients with stable CAD and persistent
inflammation. In patients with CAD, the presence of both high CRP and MCP-1 levels
could facilitate the decision for treatment with anti-inflammatory drugs.
4. Patients and Methods
4.1. Patients
The subjects of this study were 917 patients with stable CAD who had a previous
acute coronary syndrome with or without ST-segment (ST) elevation 6–12 months before.
These patients were part of the BACS-BAMI (Biomarkers in Acute Coronary Syndrome and
Biomarkers in Acute Myocardial Infarction) project, developed in five different hospitals in
Madrid (Spain), the inclusion and exclusion criteria for which were previously defined [11].
At baseline, clinical variables were recorded and plasma was withdrawn for analysis.
4.2. Ethics Statement
The research protocol conformed to the ethical guidelines of the 1975 Declaration
of Helsinki, as reflected in a priori approval by the human research committees of the
institutions participating in this study: Fundación Jiménez Díaz, Hospital Fundación
Alcorcón, Hospital de Fuenlabrada, Hospital Universitario Puerta de Hierro-Majadahonda
and Hospital Universitario de Móstoles (code 25/2007, 24 April 2007), as previously
described [35]. All patients signed informed consent documents.
4.3. Study Design
Clinical variables were recorded at baseline. Patients were seen every year at their
hospitals. The medical records were reviewed and patient status was confirmed at the end
of follow-up. As previously described [35], the primary outcome was the combination
of acute ischemic events (Non-ST acute coronary syndrome, ST-elevation myocardial
infarction (NSTEACS, STEMI), stroke and transient ischemic attack) plus heart failure and
all-cause mortality. The secondary outcomes were ischemic events and the composite
of heart failure and death. Non-ST elevation acute coronary syndrome was defined as
resting angina lasting more than 20 min in the previous 24 h, or new-onset class III-IV
angina, along with transient ST depression or T wave inversion in the electrocardiogram
considered diagnostic by the attending cardiologist or troponin elevation. ST elevation
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myocardial infarction was defined as symptoms compatible with angina lasting more
than 20 min and ST elevation in two adjacent leads in the electrocardiogram without
response to nitroglycerin, as well as troponin elevation. Past myocardial infarction was
diagnosed in the presence of new pathological Q waves in the electrocardiogram, along
with a concordant new myocardial scar identified either by echocardiography or nuclear
magnetic resonance imaging. Stroke was defined as rapid onset of a neurologic deficit
attributable to a focal vascular cause lasting more than 24 h or supported by new cerebral
ischemic lesions in imaging studies. A transient ischemic attack was defined as a transient
stroke with signs and symptoms resolving before 24 h without cerebral acute ischemic
lesions at imaging techniques. HF was a clinical diagnosis made in accordance with practice
guidelines. Events were adjudicated by at least two investigators of the study, along with a
neurologist for cerebrovascular events. Although all events were recorded for each case,
patients were excluded from the Cox regression analysis after the first event. Although the
total number of events was also described, patients that experienced more than one event
were computed only once for these analyses.
4.4. Biomarker and Analytical Studies
Plasma determinations were performed at the Laboratory of Nephrology at the Gómez-
Ulla Hospital and at the Biochemistry Laboratory at Fundación Jiménez Díaz, as previously
described [35]. The investigators who performed the laboratory studies were unaware
of clinical data. Plasma concentrations of MCP-1 and galectin-3 were determined using
commercially available enzyme-linked immunosorbent assay kits (BMS279/2, Bender
MedSystems, Burlingame, CA, USA; DCP00, R&D Systems, Minneapolis, MN, USA, re-
spectively) following the manufacturers’ instructions. Intra- and interassay coefficients of
variation were 4.6% and 5.9% for MCP-1 and 6.2% and 8.3% for galectin-3, respectively.
High-sensitive Troponin I (Hs-TnI) was assessed by direct quimioluminiscence (ADVIA
Centaur, Siemens, Erlangen, Germany), High-sensitive C-reactive protein (Hs-CRP) protein
was assessed by latex-enhanced immunoturbidimetry (ADVIA 2400 Chemistry System,
Siemens, Erlangen, Germany) and NT-proBNP by immunoassay (VITROS, Ortho Clinical
Diagnostics Raritan, West New York, NJ, USA). Lipids, glucose and creatinine determina-
tions were performed using standard methods (ADVIA 2400 Chemistry System, Siemens,
Erlangen, Germany). The estimated glomerular filtration rate (eGFR) was calculated using
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
4.5. Statistical Analysis
Quantitative data with a normal distribution are presented as the mean ± standard
deviation (SD) and were compared using the Student’s t test. Data that did not follow a
normal distribution are displayed as the median (interquartile range) and were compared
using the Mann–Whitney test. Qualitative variables are shown as percentages and were
compared with the Chi-square or the Fisher’s test when appropriate.
The concentrations of MCP-1 and NT-proBNP are expressed in terms of a standardized
variable as units of standard deviation (1-SD). The univariate Cox proportional hazard
model was used to assess the variables associated with the outcomes. Then, a multivariate
Cox hazard model was carried out, including those variables that achieved statistical
significance in univariate analyses. Risk was estimated by including age, gender, diabetes,
smoking status, hypertension, body mass index, history of cerebrovascular disease, atrial
fibrillation, ejection fraction < 40%, complete revascularization, estimated glomerular filtra-
tion rate assessed by the CKD-EPI equation, lipid levels (low density lipoprotein-cholesterol
(LDL-c), high density lipoprotein-cholesterol (HDL-c), triglycerides), therapy with antico-
agulants, aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, beta-blockers, diuretics, nitrates or nitroglycerin, complete revascularization and
biomarkers NT-proBNP and MCP-1.
A receiver operator characteristic curve analysis was performed to determine the
MCP-1 cutoff point in our patients for maximum sensitivity and highest specificity for
J. Clin. Med. 2021, 10, 1137 11 of 13
prognosis of acute ischemic events based on Youden’s index. The Kaplan–Meier survival
curve and long-rank test were used to compare time to outcome according to CRP and
MCP-1 levels.
Finally, the presence of interactions between persistent inflammation and elevated
MCP-1 levels and the effects on acute ischemic events were examined. HR rates with
95% CI were estimated for each category using CRP < 2 mg/L as the reference category.
Following this, we calculated the relative excess risk due to interaction (RERI) and the
synergy index (S) [36]. Analysis was performed with SPSS 19.0 (IBM, Armonk, NY, USA).
Variables with p < 0.05 were considered statistically significant.
Supplementary Materials: The following are available online at https://www.mdpi.com/2077-038
3/10/5/1137/s1: Table S1. Univariate Cox proportional hazards model in patients with Hs-CRP < 2 mg/L.
Table S2. Univariate Cox proportional hazards model in patients with Hs-CRP ≥ 2 mg/L.
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